MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) announced the appointment of William “Bill” Plovanic, CFA, to its Board of Directors, bringing more than 25 years of experience in capital markets, corporate strategy, and medical device operations to the company.
Plovanic currently serves as Managing Director of Healthcare Equity Research at Canaccord Genuity, where he provides research and strategic insights into the medical technology sector. He previously held multiple C-suite and board positions at Obalon Therapeutics, a publicly traded medical device firm, from 2016 to 2021, giving him firsthand experience in corporate strategy, product commercialization, and public company leadership.
“We are pleased to welcome Bill to our Board,” said Antony Koblish, Co-founder and Chief Executive Officer of TELA Bio. “He bridges the worlds of Wall Street and operating leadership. His understanding of the capital markets—paired with direct experience running a publicly held med-tech company—will help to further strengthen our strategy and drive long-term shareholder value.”
Plovanic said he is joining the board at a transformative time for the company. “I’m honored to join TELA Bio at this pivotal stage,” he said. “The company stands out as a leader redefining what is possible in soft-tissue reconstruction.”
Before his tenure at Obalon, Plovanic served in senior equity research roles at First Albany and Canaccord Genuity, where he focused on the medical technology and life sciences industries. He earned a Bachelor of Science in Finance from Bradley University and holds the Chartered Financial Analyst (CFA) designation.
The appointment reflects TELA Bio’s continued effort to expand its leadership expertise as it advances innovative solutions in soft-tissue reconstruction and builds long-term shareholder value.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.